SeaStar Medical Officer Will Present at 2026 PPETS
Kevin Chung will showcase pediatric therapy data at the Texas Children's Hospital conference this October.
Updated on Sept. 29, 2026 in Children’s Health
Live Poll
Will advancements in medical device technology reliably lower mortality rates for patients?
On October 6, 2026, SeaStar Medical Chief Medical Officer Kevin Chung will present clinical findings at the PPETS conference held in Houston. The presentation will feature data regarding the use of QUELIMMUNE, an FDA-approved device therapy for pediatric patients.
Why it matters
The conference serves as a key platform for pediatric specialists to review innovations in extracorporeal therapies. Sharing these results helps advance clinical understanding of how to manage critical immune responses in young patients.
Clinical observations for QUELIMMUNE show a 77% survival rate in treated patients, with 87.5% of survivors maintaining normal kidney function at Day 60. Additionally, the NEUTRALIZE-AKI trial currently tracks 339 adult participants.
The players
Kevin Chung
He serves as the Chief Medical Officer of SeaStar Medical and specializes in the clinical application of extracorporeal therapies.
SeaStar Medical
The company develops medical devices focused on neutralizing immune system responses to prevent organ failure in critical care settings.
Texas Children's Hospital
Based in Houston, this institution is one of the largest pediatric hospitals in the United States and serves as a major research center.
The details
The therapy works by neutralizing over-active immune cells to prevent cytokine storms and integrates directly with standard continuous renal replacement systems. These innovations are intended to improve recovery outcomes for children facing severe inflammatory conditions.
Timeline
February 2024: QUELIMMUNE received FDA Humanitarian Device Exemption approval.
February 2026: The QUELIMMUNE SAVE Registry data was published in Pediatric Nephrology.
October 6-8, 2026: The PPETS conference will be held at Texas Children's Hospital.
October 6, 2026: Kevin Chung will present his findings at 8:30 am CDT.
The Big Picture
The clinical results presented at PPETS are part of a broader trajectory of data collection that began with the NEUTRALIZE-AKI trial. These new presentations demonstrate how evidence-based extracorporeal therapies are bridging the gap between adult and pediatric critical care protocols.
The advancement of QUELIMMUNE therapy may provide new treatment options for pediatric patients suffering from severe cytokine-related inflammation. Families and caregivers should consult with nephrology specialists to determine how these integrated renal therapies affect long-term recovery plans.
The takeaway
Ongoing clinical research continues to provide life-saving insights into how medical technology can manage complex immune responses. Providers are encouraged to monitor these developments as new registry data becomes available to refine pediatric care strategies.
Further reading
Learn more about the latest innovations in Children’s Health.
Live Poll
Will advancements in medical device technology reliably lower mortality rates for patients?
